Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mark B, Stoopler"'
Autor:
William A. Bulman, Luke Benvenuto, Selim M. Arcasoy, John H Spivack, Matthen Mathew, Lanyi Nora Chen, Mark B. Stoopler, Catherine A. Shu, Anjali Saqi, Thu Cao, Naiyer A. Rizvi, Bryan P. Stanifer
Publikováno v:
Lung Cancer. 146:297-302
Lung cancer is the third most common malignancy that develops in patients following solid organ transplantation and is the leading cause of cancer deaths in the general population. The aims of this study are to examine the characteristics of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abe1d53dc53ce2b13ba4044d700799f0
https://doi.org/10.1016/j.lungcan.2020.06.018
https://doi.org/10.1016/j.lungcan.2020.06.018
Autor:
Carlos A. Pagan, Galina G Lagos, Helen Fernandes, John P. Crapanzano, Catherine A. Shu, Jonas J. Heymann, Mark B. Stoopler, Naiyer A. Rizvi, Anjali Saqi, Joshua R. Sonett
Publikováno v:
American journal of clinical pathology. 154(1)
Objectives To determine concordance/discordance between morphology and molecular testing (MT) among synchronous pulmonary carcinomas using targeted next generation sequencing (NGS), with and without comprehensive molecular review (CMR), vs analyses o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80357f71402791ab391398111459220d
https://pubmed.ncbi.nlm.nih.gov/32146481
https://pubmed.ncbi.nlm.nih.gov/32146481
Autor:
Ladan Fazlollahi, David Swinarski, John P. Crapanzano, Naiyer A. Rizvi, Mehrvash Haghighi, Adrian G. Sacher, Joshua R. Sonett, Jonas J. Heymann, Anjali Saqi, Catherine A. Shu, Mark B. Stoopler, William A. Bulman, Carlos A. Pagan
Publikováno v:
Cancer Cytopathology. 125:896-907
Background One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b34d5b76024e4ec71562bdad649ef86b
https://doi.org/10.1002/cncy.21937
https://doi.org/10.1002/cncy.21937
Autor:
Michael B. Sisti, Andrew B. Lassman, Tzlil Rozenblat, Yasir H. Qureshi, Shumaila Saad, Tony J. C. Wang, Andrew Yaeh, Jeffrey N. Bruce, Balazs Halmos, Tavish Nanda, Ashish Jani, Steven R. Isaacson, Jeraldine Lesser, Mark B. Stoopler, Guy M. McKhann, Simon K. Cheng
Publikováno v:
Neuro-Oncology. 17:1022-1028
BACKGROUND We investigated effects of genetic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral oncogene homolog (KRAS) on overall survival (OS) and local control after stereotacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3559be31835a44a08a20e03e70b02d8
https://doi.org/10.1093/neuonc/nov043
https://doi.org/10.1093/neuonc/nov043
Autor:
Jonas J, Heymann, William A, Bulman, David, Swinarski, Carlos A, Pagan, John P, Crapanzano, Mehrvash, Haghighi, Ladan, Fazlollahi, Mark B, Stoopler, Joshua R, Sonett, Adrian G, Sacher, Catherine A, Shu, Naiyer A, Rizvi, Anjali, Saqi
Publikováno v:
Cancer cytopathology. 125(12)
One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression. The curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bfaea7af2c7b8a6e110d59ac94878fad
https://pubmed.ncbi.nlm.nih.gov/29024471
https://pubmed.ncbi.nlm.nih.gov/29024471
Autor:
Balazs Halmos, Tom K. Hei, Samuel P. Heilbroner, Joshua R. Sonett, Kunal R. Chaudhary, Simon K. Cheng, Mark B. Stoopler, Sherry X. Yan, Catherine A. Shu, Tony J. C. Wang
Publikováno v:
Journal of Clinical Medicine
Volume 8
Issue 5
Journal of Clinical Medicine, Vol 8, Iss 5, p 575 (2019)
Volume 8
Issue 5
Journal of Clinical Medicine, Vol 8, Iss 5, p 575 (2019)
Introduction: Locally advanced non-small cell lung cancer (NSCLC) is highly resistant to chemoradiotherapy, and many cancer patients experience chronic stress. Studies that suggest stimulation of &beta
adrenergic receptors (&beta
AR) promot
adrenergic receptors (&beta
AR) promot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5dc0e130eb4353428d9592507834991
https://doi.org/10.3390/jcm8050575
https://doi.org/10.3390/jcm8050575
Autor:
William A. Bulman, Mark B. Stoopler, Anjali Saqi, Julia A. Elvin, Vincent A. Miller, Siraj M. Ali, Joel R. Greenbowe, James Suh, David M. DiBardino
Publikováno v:
Clinical lung cancer. 17(6)
Background Next-generation sequencing is available for assessing genomic alterations in non–small-cell lung cancer (NSCLC), although the performance characteristics and clinical utility has not been well characterized. This technique can be used to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2380f98dc257ff68429698c44ec8f64
https://pubmed.ncbi.nlm.nih.gov/27378171
https://pubmed.ncbi.nlm.nih.gov/27378171
Autor:
Mark E. Ginsburg, Matthew Bacchetta, Mark B. Stoopler, Seth Crockford, Christina Wu, Anshu K. Jain, Lyall A. Gorenstein, Balazs Halmos, Sherry Yan, Joshua R. Sonett, Simon K. Cheng, Frank D'Ovidio
Publikováno v:
Journal of Thoracic Oncology. 12:S860-S861
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bb94ef4f137e4548586c169e96b2751
https://doi.org/10.1016/j.jtho.2016.11.1170
https://doi.org/10.1016/j.jtho.2016.11.1170
Autor:
May-Lin Wilgus, Lyall A. Gorenstein, Alain C. Borczuk, Charles A. Powell, Joshua R. Sonett, Mark B. Stoopler, Mark E. Ginsburg
Publikováno v:
Cancer. 117:2186-2191
BACKGROUND: Lung adenocarcinoma invasion and metastasis arises from autocrine and paracrine signaling events between tumor epithelial cells and the stromal microenvironment that is mediated in part by transforming growth factor-β (TGF-β) signaling.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc800f6bb15d3b4f7f25e62eb070f8ce
https://doi.org/10.1002/cncr.25768
https://doi.org/10.1002/cncr.25768
Autor:
Susana Hernandez, Naiyer A. Rizvi, Matthew Bacchetta, Tiffany Negri, Anjali Saqi, Stephanie Smith-Marrone, Codruta Chiuzan, Vijeta Patel, Mark B. Stoopler, Joshua R. Sonett, Justin F. Gainor, Adrian G. Sacher, Claud Grigg, Frank D'Ovidio, Mark M. Awad, Robert Garofano, Catherine A. Shu
Publikováno v:
Journal of Clinical Oncology. 36:8532-8532
8532Background: Neoadjuvant chemotherapy is an accepted treatment approach for resectable NSCLC. Major pathologic response (mPR) defined as ≥ 90% tumor necrosis is seen in 20% of patients (pts) rec...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44e6ab4382b19ca03101cc0b2fdfe2c2
https://doi.org/10.1200/jco.2018.36.15_suppl.8532
https://doi.org/10.1200/jco.2018.36.15_suppl.8532